N/A
Completed N=163,720
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Dihydropyridine Calcium Channel Blockers Versus Hydrochlorothiazide
Source: ClinicalTrials.gov NCT05125224 ↗Enrolled (actual)
163,720
Serious AEs
—
Results posted
Nov 2025
Primary outcomePrimary: Time to Dementia Onset — 17.1; 13.7; 20.8; 20.6 Incidence rate per 1000 person year
Summary
This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Time to Dementia Onset |
17.1; 13.7; 20.8; 20.6; 15.6; 13.1 | — |
Eligibility Criteria
Please see https://docs.google.com/spreadsheets/d/1VlyY3zcxoRp0tH7yv8rSOEggSO6WQ0VYEjq-6KlSSt8/edit?usp=sharing or Appendix A for full code and algorithm definitions.
Medicare timeframe: 2008 to 2018 (end of data availability). CRPD timeframe: 2007 to 2018
Inclusion Criteria
- 1. Aged > 65 years on the index date
- 2. For Medicare - Enrollment in Medicare Part A, B, and D with no HMO coverage for 365 days prior to and including cohort entry date
- 3. At least two claims with hypertension diagnosis recorded in 365 days prior to cohort entry date
Exclusion Criteria
- 1. Prior history of dementia measured anytime prior to cohort entry date
- 2. Prior use of dihydropyridine CCBs, hydrochlorothiazide, or other antihypertensives anytime prior to cohort entry date
Data sourced from ClinicalTrials.gov (NCT05125224). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.